메뉴 건너뛰기




Volumn 187, Issue 1, 2014, Pages 6-13

Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer

Author keywords

AZD7762; Chemosensitivity; CHK1; Combination therapies; NSCLC cell lines; Radiosensitivity

Indexed keywords

AZD7762; CHEMOSENSITIVITY; CHK1; COMBINATION THERAPIES; NSCLC CELL LINES; RADIOSENSITIVITY;

EID: 84894098346     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.12.016     Document Type: Article
Times cited : (22)

References (36)
  • 2
    • 33847276516 scopus 로고    scopus 로고
    • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-arm cooperative study in Japan
    • Y. Ohe, Y. Ohashi, and K. Kubota et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan Ann Oncol 18 2007 317
    • (2007) Ann Oncol , vol.18 , pp. 317
    • Ohe, Y.1    Ohashi, Y.2    Kubota, K.3
  • 3
    • 0037050352 scopus 로고    scopus 로고
    • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    • J.H. Schiller, D. Harrington, and C.P. Belani et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92
    • (2002) N Engl J Med , vol.346 , pp. 92
    • Schiller, J.H.1    Harrington, D.2    Belani, C.P.3
  • 4
    • 0031741679 scopus 로고    scopus 로고
    • Oxaliplatin: A review of preclinical and clinical studies
    • E. Raymond, S.G. Chaney, A. Taamma, and E. Cvitkovic Oxaliplatin: a review of preclinical and clinical studies Ann Oncol 9 1998 1053
    • (1998) Ann Oncol , vol.9 , pp. 1053
    • Raymond, E.1    Chaney, S.G.2    Taamma, A.3    Cvitkovic, E.4
  • 5
    • 77955362168 scopus 로고    scopus 로고
    • Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: An international validation study
    • C.M. Bryant, D.L. Albertus, and S. Kim et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study PLoS One 5 2010 e11712
    • (2010) PLoS One , vol.5 , pp. 11712
    • Bryant, C.M.1    Albertus, D.L.2    Kim, S.3
  • 6
    • 54549094903 scopus 로고    scopus 로고
    • Somatic mutations affect key pathways in lung adenocarcinoma
    • L. Ding, G. Getz, and D.A. Wheeler et al. Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069
    • (2008) Nature , vol.455 , pp. 1069
    • Ding, L.1    Getz, G.2    Wheeler, D.A.3
  • 7
    • 75749097259 scopus 로고    scopus 로고
    • Targeted therapies for non-small cell lung cancer
    • W.C. Dempke, T. Suto, and M. Reck Targeted therapies for non-small cell lung cancer Lung Cancer 67 2010 257
    • (2010) Lung Cancer , vol.67 , pp. 257
    • Dempke, W.C.1    Suto, T.2    Reck, M.3
  • 8
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • E.L. Kwak, Y.J. Bang, and D.R. Camidge et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693
    • (2010) N Engl J Med , vol.363 , pp. 1693
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, D.R.3
  • 10
    • 79955720082 scopus 로고    scopus 로고
    • Anticancer therapy with checkpoint inhibitors: What, where and when?
    • M.D. Garrett, and I. Collins Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci 32 2011 308
    • (2011) Trends Pharmacol Sci , vol.32 , pp. 308
    • Garrett, M.D.1    Collins, I.2
  • 11
    • 0034707047 scopus 로고    scopus 로고
    • The DNA damage response: Putting checkpoints in perspective
    • B.B. Zhou, and S.J. Elledge The DNA damage response: putting checkpoints in perspective Nature 408 2000 433
    • (2000) Nature , vol.408 , pp. 433
    • Zhou, B.B.1    Elledge, S.J.2
  • 12
    • 0035093737 scopus 로고    scopus 로고
    • DNA double-strand breaks: Signaling, repair and the cancer connection
    • K.K. Khanna, and S.P. Jackson DNA double-strand breaks: signaling, repair and the cancer connection Nat Genet 27 2001 247
    • (2001) Nat Genet , vol.27 , pp. 247
    • Khanna, K.K.1    Jackson, S.P.2
  • 13
    • 13944266820 scopus 로고    scopus 로고
    • The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
    • C.S. Sorensen, L.T. Hansen, and J. Dziegielewski et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair Nat Cell Biol 7 2005 195
    • (2005) Nat Cell Biol , vol.7 , pp. 195
    • Sorensen, C.S.1    Hansen, L.T.2    Dziegielewski, J.3
  • 14
    • 58149500122 scopus 로고    scopus 로고
    • Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells
    • L.A. Parsels, M.A. Morgan, and D.M. Tanska et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells Mol Cancer Ther 8 2009 45
    • (2009) Mol Cancer Ther , vol.8 , pp. 45
    • Parsels, L.A.1    Morgan, M.A.2    Tanska, D.M.3
  • 15
    • 77950650401 scopus 로고    scopus 로고
    • In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762
    • J.B. Mitchell, R. Choudhuri, and K. Fabre et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762 Clin Cancer Res 16 2010 2076
    • (2010) Clin Cancer Res , vol.16 , pp. 2076
    • Mitchell, J.B.1    Choudhuri, R.2    Fabre, K.3
  • 16
    • 77953770987 scopus 로고    scopus 로고
    • Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair
    • M.A. Morgan, L.A. Parsels, and L. Zhao et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair Cancer Res 70 2010 4972
    • (2010) Cancer Res , vol.70 , pp. 4972
    • Morgan, M.A.1    Parsels, L.A.2    Zhao, L.3
  • 17
    • 39749185974 scopus 로고    scopus 로고
    • Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest
    • A.A. Levesque, A.A. Fanous, A. Poh, and A. Eastman Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest Mol Cancer Ther 7 2008 252
    • (2008) Mol Cancer Ther , vol.7 , pp. 252
    • Levesque, A.A.1    Fanous, A.A.2    Poh, A.3    Eastman, A.4
  • 18
    • 0035399861 scopus 로고    scopus 로고
    • Cytokine-responsive gene-2/IFN-inducible protein-10 expression in multiple models of liver and bile duct injury suggests a role in tissue regeneration
    • L.G. Koniaris, T. Zimmers-Koniaris, E.C. Hsiao, K. Chavin, J.V. Sitzmann, and J.M. Farber Cytokine-responsive gene-2/IFN-inducible protein-10 expression in multiple models of liver and bile duct injury suggests a role in tissue regeneration J Immunol 167 2001 399
    • (2001) J Immunol , vol.167 , pp. 399
    • Koniaris, L.G.1    Zimmers-Koniaris, T.2    Hsiao, E.C.3    Chavin, K.4    Sitzmann, J.V.5    Farber, J.M.6
  • 19
    • 33751581196 scopus 로고    scopus 로고
    • Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics
    • Z. Chen, Z. Xiao, and W.Z. Gu et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics Int J Cancer 119 2006 2784
    • (2006) Int J Cancer , vol.119 , pp. 2784
    • Chen, Z.1    Xiao, Z.2    Gu, W.Z.3
  • 20
    • 49149129916 scopus 로고    scopus 로고
    • Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study
    • K. Shedden, J.M. Taylor, and S.A. Enkemann et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study Nat Med 14 2008 822
    • (2008) Nat Med , vol.14 , pp. 822
    • Shedden, K.1    Taylor, J.M.2    Enkemann, S.A.3
  • 21
    • 52949139387 scopus 로고    scopus 로고
    • AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
    • S.D. Zabludoff, C. Deng, and M.R. Grondine et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Mol Cancer Ther 7 2008 2955
    • (2008) Mol Cancer Ther , vol.7 , pp. 2955
    • Zabludoff, S.D.1    Deng, C.2    Grondine, M.R.3
  • 22
    • 0035710746 scopus 로고    scopus 로고
    • Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method
    • K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method Methods 25 2001 402
    • (2001) Methods , vol.25 , pp. 402
    • Livak, K.J.1    Schmittgen, T.D.2
  • 23
    • 84863288259 scopus 로고    scopus 로고
    • Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma
    • L. Lin, A.J. Bass, and W.W. Lockwood et al. Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma Proc Natl Acad Sci U S A 109 2012 4251
    • (2012) Proc Natl Acad Sci U S A , vol.109 , pp. 4251
    • Lin, L.1    Bass, A.J.2    Lockwood, W.W.3
  • 24
    • 0035480005 scopus 로고    scopus 로고
    • Tissue microarrays (TMAs) for high-throughput molecular pathology research
    • A. Nocito, J. Kononen, O.P. Kallioniemi, and G. Sauter Tissue microarrays (TMAs) for high-throughput molecular pathology research Int J Cancer 94 2001 1
    • (2001) Int J Cancer , vol.94 , pp. 1
    • Nocito, A.1    Kononen, J.2    Kallioniemi, O.P.3    Sauter, G.4
  • 25
    • 0034018946 scopus 로고    scopus 로고
    • Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
    • S. Wang, M.H. Saboorian, E. Frenkel, L. Hynan, S.T. Gokaslan, and R. Ashfaq Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays J Clin Pathol 53 2000 374
    • (2000) J Clin Pathol , vol.53 , pp. 374
    • Wang, S.1    Saboorian, M.H.2    Frenkel, E.3    Hynan, L.4    Gokaslan, S.T.5    Ashfaq, R.6
  • 26
    • 0021244486 scopus 로고
    • Mean inactivation dose: A useful concept for intercomparison of human cell survival curves
    • B. Fertil, H. Dertinger, A. Courdi, and E.P. Malaise Mean inactivation dose: a useful concept for intercomparison of human cell survival curves Radiat Res 99 1984 73
    • (1984) Radiat Res , vol.99 , pp. 73
    • Fertil, B.1    Dertinger, H.2    Courdi, A.3    Malaise, E.P.4
  • 28
    • 84859611140 scopus 로고    scopus 로고
    • Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy
    • M. Bartucci, S. Svensson, and P. Romania et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy Cell Death Diff 19 2012 768
    • (2012) Cell Death Diff , vol.19 , pp. 768
    • Bartucci, M.1    Svensson, S.2    Romania, P.3
  • 29
    • 84874411631 scopus 로고    scopus 로고
    • Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells
    • D. Minami, N. Takigawa, and H. Takeda et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells Mol Cancer Res 11 2013 140
    • (2013) Mol Cancer Res , vol.11 , pp. 140
    • Minami, D.1    Takigawa, N.2    Takeda, H.3
  • 30
    • 0035829685 scopus 로고    scopus 로고
    • Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
    • K. Koniaras, A.R. Cuddihy, H. Christopoulos, A. Hogg, and M.J. O'Connell Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells Oncogene 20 2001 7453
    • (2001) Oncogene , vol.20 , pp. 7453
    • Koniaras, K.1    Cuddihy, A.R.2    Christopoulos, H.3    Hogg, A.4    O'Connell, M.J.5
  • 31
    • 84864658154 scopus 로고    scopus 로고
    • Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma
    • O.D. Roe, A. Szulkin, and E. Anderssen et al. Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma PLoS One 7 2012 e40521
    • (2012) PLoS One , vol.7 , pp. 40521
    • Roe, O.D.1    Szulkin, A.2    Anderssen, E.3
  • 32
    • 78649896033 scopus 로고    scopus 로고
    • Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach
    • H. Yao, Z. Yang, and Y. Li Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach Zhong Nan Da Xue Xue Bao Yi Xue Ban 35 2010 1080
    • (2010) Zhong Nan da Xue Xue Bao Yi Xue Ban , vol.35 , pp. 1080
    • Yao, H.1    Yang, Z.2    Li, Y.3
  • 33
    • 84865635727 scopus 로고    scopus 로고
    • Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition
    • V.A. Venkatesha, L.A. Parsels, and J.D. Parsels et al. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition Neoplasia 14 2012 519
    • (2012) Neoplasia , vol.14 , pp. 519
    • Venkatesha, V.A.1    Parsels, L.A.2    Parsels, J.D.3
  • 34
    • 84455174466 scopus 로고    scopus 로고
    • Treatment with the Chk1 inhibitor Go6976 enhances cisplatin cytotoxicity in SCLC cells
    • R. Thompson, M. Meuth, P. Woll, Y. Zhu, and S. Danson Treatment with the Chk1 inhibitor Go6976 enhances cisplatin cytotoxicity in SCLC cells Int J Oncol 40 2012 194
    • (2012) Int J Oncol , vol.40 , pp. 194
    • Thompson, R.1    Meuth, M.2    Woll, P.3    Zhu, Y.4    Danson, S.5
  • 35
    • 18544384850 scopus 로고    scopus 로고
    • Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics
    • Z. Xiao, J. Xue, D. Semizarov, T.J. Sowin, S.H. Rosenberg, and H. Zhang Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics Int J Cancer 115 2005 528
    • (2005) Int J Cancer , vol.115 , pp. 528
    • Xiao, Z.1    Xue, J.2    Semizarov, D.3    Sowin, T.J.4    Rosenberg, S.H.5    Zhang, H.6
  • 36
    • 79957916529 scopus 로고    scopus 로고
    • Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition
    • L.A. Parsels, Y. Qian, and D.M. Tanska et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition Clin Cancer Res 17 2011 3706
    • (2011) Clin Cancer Res , vol.17 , pp. 3706
    • Parsels, L.A.1    Qian, Y.2    Tanska, D.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.